Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
168.65 +6.74 (+4.16%) 15:51 ET [NASDAQ]
168.42 x 100 169.00 x 8
Realtime by (Cboe BZX)
168.42 x 100 169.00 x 8
Realtime - - (-) -
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
163.05
Day High
168.81
Open 164.75
Previous Close 161.91 161.91
Volume 107,081 107,081
Avg Vol 329,020 329,020
Stochastic %K 50.10% 50.10%
Weighted Alpha -1.25 -1.25
5-Day Change -0.91 (-0.54%) -0.91 (-0.54%)
52-Week Range 141.72 - 219.34 141.72 - 219.34
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,678,876
  • Shares Outstanding, K 28,898
  • Annual Sales, $ 290,520 K
  • Annual Income, $ 89,160 K
  • EBIT $ 66 M
  • EBITDA $ 72 M
  • 60-Month Beta 0.75
  • Price/Sales 16.77
  • Price/Cash Flow 36.35
  • Price/Book 5.12

Options Overview Details

View History
  • Implied Volatility 62.94% ( -4.51%)
  • Historical Volatility 45.31%
  • IV Percentile 80%
  • IV Rank 69.97%
  • IV High 75.29% on 08/02/24
  • IV Low 34.16% on 11/14/24
  • Put/Call Vol Ratio 2.19
  • Today's Volume 51
  • Volume Avg (30-Day) 145
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 3,392
  • Open Int (30-Day) 4,468

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.35
  • Number of Estimates 4
  • High Estimate 1.56
  • Low Estimate 1.21
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +4,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
150.10 +11.93%
on 04/09/25
Period Open: 187.15
197.94 -15.13%
on 03/25/25
-19.15 (-10.23%)
since 03/21/25
3-Month
146.00 +15.07%
on 02/12/25
Period Open: 153.46
197.94 -15.13%
on 03/25/25
+14.54 (+9.47%)
since 01/22/25
52-Week
141.72 +18.54%
on 01/14/25
Period Open: 157.25
219.34 -23.41%
on 07/26/24
+10.75 (+6.84%)
since 04/22/24

Most Recent Stories

More News
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

KRYS : 168.65 (+4.16%)
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational pipeline candidate FT819 for the treatment of active...

KRYS : 168.65 (+4.16%)
JAZZ : 103.26 (+2.91%)
ADMA : 21.29 (+8.40%)
FATE : 1.3600 (+8.80%)
Ironwood Shares Tank on Regulatory Update for Apraglutide

Shares of Ironwood Pharmaceuticals IRWD plunged 31.5% yesterday after it announced regulatory updates on the next-generation GLP-2 analog, apraglutide, which is being developed for treating short bowel...

KRYS : 168.65 (+4.16%)
IRWD : 0.7111 (+0.88%)
JAZZ : 103.26 (+2.91%)
ADMA : 21.29 (+8.40%)
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to protect...

KRYS : 168.65 (+4.16%)
JAZZ : 103.26 (+2.91%)
ADMA : 21.29 (+8.40%)
ARCT : 12.16 (+10.55%)
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Shares of TG Therapeutics, Inc. TGTX have rallied 29.5% in the past three months against the industry’s decline of 11.2%.The company’s sole marketed drug Briumvi (ublituximab-xiiy) was approved by...

TGTX : 37.86 (+2.41%)
KRYS : 168.65 (+4.16%)
DTIL : 5.36 (+4.48%)
JAZZ : 103.26 (+2.91%)
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

KRYS : 168.65 (+4.16%)
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime...

KRYS : 168.65 (+4.16%)
JAZZ : 103.26 (+2.91%)
DVAX : 10.73 (+2.78%)
AXSM : 103.89 (+0.86%)
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and oral orexin 2 receptor agonist, ALKS 2680, in adults with idiopathic hypersomnia...

KRYS : 168.65 (+4.16%)
JAZZ : 103.26 (+2.91%)
ALKS : 27.03 (+0.11%)
AXSM : 103.89 (+0.86%)
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

Beam Therapeutics Inc. BEAM announced that the FDA has cleared the investigational new drug (IND) application to begin clinical studies on its pipeline candidate, BEAM-302, for the treatment of alpha-1...

BEAM : 19.07 (+4.55%)
KRYS : 168.65 (+4.16%)
JAZZ : 103.26 (+2.91%)
DVAX : 10.73 (+2.78%)
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

KRYS : 168.65 (+4.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 177.40
2nd Resistance Point 173.95
1st Resistance Point 167.93
Last Price 168.65
1st Support Level 158.46
2nd Support Level 155.01
3rd Support Level 148.99

See More

52-Week High 219.34
Fibonacci 61.8% 189.69
Fibonacci 50% 180.53
Fibonacci 38.2% 171.37
Last Price 168.65
52-Week Low 141.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro